A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The safety and comfort of repeated administrations of a topically-administered ophthalmic
formulation of MC-1101 will be established through investigator assessments and subject
reporting over a 3 day period. Safety assessments will be performed on both normal, healthy
subjects as well as those with the signs and symptoms of early non-exudative age-related
macular degeneration (dry AMD).